NSCLC PDX Ex Vivo Imaging & Cell Line In Vitro Screens
In partnership with PhenoVista Biosciences (see our latest Press Release), we are now enrolling for a high throughput NSCLC PDX Ex Vivo Imaging Screen and In Vitro Cell Line Screen.
ENROLLMENT OPEN NOW THROUGH January 24th
- Choose from 30 low passage PDX models and/or 45 human cell lines.
- PDX models are well characterized within Vivo SOC & patient responses clinical annotation, and NGS.
- FREE SOC ex vivo/in vitro response will be provided for each model.
- PDX Ex Vivo Screen readouts are Cell Viability normalized to DMSO, with drug IC50s.
- In Vitro Cell Line readout is proliferation/cell viability by Cell Titer-Glo.
- Enrollment is open until January 24th, 2020.
Available on first-come, first-serve basis